UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 187

Sortiert nach

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Annals of oncology, 2016-05, Vol.27 (5), p.920-926

2016

Volltextzugriff (PDF)

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Annals of oncology, 2018-10, Vol.29, p.viii713-viii713

2018

Volltextzugriff (PDF)

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

Annals of oncology, 2018-11, Vol.29, p.ix175-ix175

2018

Volltextzugriff (PDF)

RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

European journal of cancer (1990), 2016-12, Vol.69, p.S35-S35

2016

Volltextzugriff (PDF)

Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

European journal of cancer (1990), 2016-12, Vol.69, p.S5-S6

2016

Volltextzugriff (PDF)

Monoclonal antibody-based therapies for hematologic malignancies

Journal of clinical oncology, 1998-11, Vol.16 (11), p.3691-3710

1998

Volltextzugriff (PDF)

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma

International journal of hematology, 2002-12, Vol.76 (5), p.401-410

Multani, P

2002

Volltextzugriff (PDF)

Non-Hodgkin's lymphoma: review of conventional treatments

Current pharmaceutical biotechnology, 2001-12, Vol.2 (4), p.279

2001

Volltextzugriff (PDF)

A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

Annals of oncology, 2017-09, Vol.28, p.v612-v612

2017

Volltextzugriff (PDF)

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii106-iii106

2017

Volltextzugriff (PDF)

8LBA - Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

European journal of cancer (1990), 2016-12, Vol.69, p.S5-S6

2016

Volltextzugriff (PDF)

OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1783-S1783

2017

Volltextzugriff (PDF)

85 - RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

European journal of cancer (1990), 2016-12, Vol.69, p.S35-S35

2016

Volltextzugriff (PDF)

Improved efficacy response attributed to diagnostic selection – Interim results of the phase 1 experience from ALKA-372-001

Annals of oncology, 2016-10, Vol.27, p.vi42-vi42

2016

Volltextzugriff (PDF)

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S321-S322

2018

Volltextzugriff (PDF)

OS06.4 Identification of novel NTRK fusion in glioneuronal tumors and radiographic response following therapy with an NTRK inhibitor

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii11-iii11

2017

Volltextzugriff (PDF)

Secondary Acute Myelogenous Leukemia with MLL Gene Rearrangement Following Radioimmunotherapy (RAIT) for Non-Hodgkin's Lymphoma

Leukemia & lymphoma, 2002-11, Vol.43 (11), p.2145-2149

2002

Volltextzugriff (PDF)

A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S143-S143

2016

Volltextzugriff (PDF)

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma : Monoclonal Antibody Therapy for B-Cell lymphoma

International journal of hematology, 2002, Vol.76 (5), p.401-410

MULTANI, P

2002

Volltextzugriff (PDF)

High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma : a phase II study

Bone marrow transplantation (Basingstoke), 2000, Vol.25 (1), p.19-24

2000

Volltextzugriff (PDF)

Melanoma

Cancer chemotherapy and biological response modifiers, 1999, Vol.18, p.470

1999

Volltextzugriff (PDF)

LBA4Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

LBA17Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Antimetabolites

Cancer chemotherapy and biological response modifiers, 1999, Vol.18, p.1

1999

Volltextzugriff (PDF)

Translational research : Walking the bridge between idea and cure-seventeenth Bruce F. Cain memorial award lecture

Cancer research (Chicago, Ill.), 1998-10, Vol.58 (19), p.4211-4216

1998

Volltextzugriff (PDF)

1 – 25 von 187

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(171)

Publikationsform

Artikel
(181)
Tagungsberichte
(6)

Sprache

Englisch
(187)
Japanisch
(20)

Erscheinungsjahr

n.n

Thema

Science & Technology
(108)
Physical Sciences
(46)
Life Sciences & Biomedicine
(43)
Physics
(40)
Humans
(30)
Exact Sciences And Technology
(27)
Technology
(22)
Physics, Condensed Matter
(21)
Materials Science
(20)
Physics, Applied
(19)
Animals
(16)
Condensed Matter: Electronic Structure, Electrical, Magnetic, And Optical Properties
(16)
Materials Science, Multidisciplinary
(15)
Oncology
(14)
Biological And Medical Sciences
(13)
Mutation
(11)
Chemistry
(10)
Multidisciplinary Sciences
(10)
Science & Technology - Other Topics
(10)
Female
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

Monoclonal antibody-based therapies for hematologic malignancies

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma

Non-Hodgkin's lymphoma: review of conventional treatments

A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

8LBA - Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

85 - RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

Improved efficacy response attributed to diagnostic selection – Interim results of the phase 1 experience from ALKA-372-001

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

OS06.4 Identification of novel NTRK fusion in glioneuronal tumors and radiographic response following therapy with an NTRK inhibitor

Secondary Acute Myelogenous Leukemia with MLL Gene Rearrangement Following Radioimmunotherapy (RAIT) for Non-Hodgkin's Lymphoma

A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma : Monoclonal Antibody Therapy for B-Cell lymphoma

High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma : a phase II study

Melanoma

LBA4Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

LBA17Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Antimetabolites

Translational research : Walking the bridge between idea and cure-seventeenth Bruce F. Cain memorial award lecture

Aktive Filter

Suchergebnisse filtern